Lidija Covic Selected Research

PAR-1 Receptor

12/2020	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study.
12/2019	MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
7/2018	Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach.
6/2011	Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury.
8/2009	Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.
12/2007	'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage.
3/2006	Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
3/2006	Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lidija Covic Research Topics

Disease

13	Neoplasms (Cancer) 03/2022 - 03/2006
11	Thrombosis (Thrombus) 01/2021 - 11/2003
9	Inflammation (Inflammations) 01/2021 - 11/2003
4	Breast Neoplasms (Breast Cancer) 03/2022 - 03/2006
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 01/2016
4	Acute Coronary Syndrome 12/2020 - 01/2005
4	Neoplasm Metastasis (Metastasis) 12/2019 - 08/2009
3	Non-alcoholic Fatty Liver Disease 12/2022 - 10/2016
3	Hemorrhage 01/2021 - 12/2004
3	Necrosis 12/2020 - 07/2012
3	Ovarian Neoplasms (Ovarian Cancer) 07/2018 - 07/2010
3	Vascular System Injuries 08/2013 - 06/2011
3	Sepsis (Septicemia) 01/2013 - 12/2007
2	Fibrosis (Cirrhosis) 12/2022 - 10/2016
2	Atherosclerosis 01/2021 - 01/2018
2	Carcinoma (Carcinomatosis) 12/2019 - 07/2010
2	Lymphoma (Lymphomas) 02/2012 - 03/2008
2	Hyperplasia 12/2011 - 09/2006
1	Insulin Resistance 12/2022
1	Triple Negative Breast Neoplasms 03/2022
1	Carotid Artery Injuries 01/2021
1	Osteosarcoma (Osteogenic Sarcoma) 12/2019
1	Sarcoma (Soft Tissue Sarcoma) 12/2019
1	Bulimia (Binge Eating) 01/2019
1	Pruritus (Itching) 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Dermatitis 01/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 10/2016
1	Liver Diseases (Liver Disease) 10/2016
1	Rupture 08/2013
1	Pathologic Constriction (Stenosis) 08/2013
1	Heart Failure 01/2013
1	Melanoma (Melanoma, Malignant) 07/2012
1	Carcinogenesis 07/2012
1	Lewis Lung Carcinoma 07/2012
1	Lymphoid Leukemia 02/2012
1	Hematologic Neoplasms (Hematological Malignancy) 02/2012
1	Disseminated Intravascular Coagulation 07/2011
1	Lung Neoplasms (Lung Cancer) 07/2011
1	Cytokine Release Syndrome 07/2011

Drug/Important Bio-Agent (IBA)

12	Peptide Hydrolases (Proteases)FDA Link 12/2022 - 03/2008
10	Thrombin FDA Link 03/2022 - 11/2003
8	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 03/2022 - 02/2005
8	PAR-1 ReceptorIBA 12/2020 - 03/2006
7	Metalloproteases (Metalloproteinases)IBA 01/2021 - 09/2008
4	Matrix Metalloproteinases (MMPs)IBA 01/2013 - 03/2006
4	Thrombin Receptors (Thrombin Receptor)IBA 07/2012 - 04/2002
4	Proteinase-Activated ReceptorsIBA 09/2008 - 02/2005
3	GTP-Binding Proteins (G-Protein)IBA 07/2012 - 09/2008
2	PAR-2 ReceptorIBA 12/2022 - 11/2019
2	LipidsIBA 01/2021 - 11/2019
2	Collagenases (Collagenase)FDA Link 01/2021 - 07/2012
2	CytokinesIBA 12/2019 - 10/2016
2	Clopidogrel (Plavix)FDA Link 05/2019 - 07/2012
2	bivalirudin (Angiomax)FDA Link 05/2019 - 01/2018
2	CollagenIBA 10/2016 - 07/2012
2	Bevacizumab (Avastin)FDA Link 04/2013 - 07/2011
2	Matrix Metalloproteinase 1 (Interstitial Collagenase)IBA 07/2011 - 03/2006
2	PZ-128 peptideIBA 07/2011 - 08/2009
1	Glucose (Dextrose)FDA LinkGeneric 12/2022
1	Angiotensin IIIBA 03/2022
1	ClaudinsIBA 03/2022
1	ferric chlorideIBA 01/2021
1	Interleukin-8 (Interleukin 8)IBA 12/2019
1	Small Interfering RNA (siRNA)IBA 12/2019
1	Proteins (Proteins, Gene)FDA Link 12/2019
1	Protease Inhibitors (Protease Inhibitor)IBA 12/2019
1	CholesterolIBA 11/2019
1	Prasugrel Hydrochloride FDA Link 05/2019
1	Blood Glucose (Blood Sugar)IBA 01/2019
1	Trace amine-associated receptor 1IBA 01/2019
1	OxazoloneIBA 01/2019
1	DinitrofluorobenzeneIBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	Insulin (Novolin)FDA Link 01/2019
1	Wasp Venoms (Venom, Wasp)IBA 01/2019
1	Pharmaceutical PreparationsIBA 07/2018
1	Choline (Choline Chloride)IBA 10/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2016
1	Methionine (L-Methionine)FDA Link 10/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2016
1	Alanine Transaminase (SGPT)IBA 10/2016
1	Carbon Tetrachloride (Tetrachloromethane)IBA 10/2016
1	Triglycerides (Triacylglycerol)IBA 10/2016
1	Monoclonal AntibodiesIBA 04/2013
1	matrigelIBA 04/2013
1	Immunoglobulin G (IgG)IBA 04/2013
1	Matrix Metalloproteinase InhibitorsIBA 01/2013
1	Hemostatics (Antihemorrhagics)IBA 07/2012
1	Chemokine ReceptorsIBA 02/2012
1	Rituximab (Mabthera)FDA Link 02/2012
1	Dacarbazine (DIC)FDA LinkGeneric 07/2011
1	antineoplaston A10 (A 10)IBA 07/2011

Therapy/Procedure

10	Therapeutics 03/2022 - 01/2005
5	Percutaneous Coronary Intervention 05/2019 - 12/2004
2	Glycemic Control 12/2022 - 01/2019
2	Stents 05/2019 - 01/2013
1	Intravenous Infusions 01/2016
1	Immunotherapy 02/2012
1	Ligation 12/2011